The effect of leflunomide on B-cell lymphocytes in vitiligo | ||
| Minia Journal of Medical Research | ||
| Articles in Press, Accepted Manuscript, Available Online from 11 August 2024 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjmr.2024.299190.1734 | ||
| Authors | ||
| Mira Ahmed* 1; maha hussien ragaie2; Manal Gabril3; Sherif Shoukry Awad4 | ||
| 1dermatology department | ||
| 2dermatology, venereology and STDs Minia university faculty of medicine | ||
| 3Department of Pathology and laboratory medicine, Western University, Ontario, Canada | ||
| 4Department of Dermatology, STDs and Andrology, Faculty of Medicine, Minia University, Minia, Egypt | ||
| Abstract | ||
| Abstract: Background: Vitiligo is a long-lasting pigmentary skin disease. It is distinguished by the demise of melanocytes in the skin. It significantly affects the quality of life of patients. Its source remains unknown. B lymphocytes have a significant role in autoimmune process by producing autoantibodies. Leflunomide (LF) is an immunomodulator and a member of the disease-modifying antirheumatic family of drugs (DMARDs). Aims: Immunohistochemical expression of CD20 in lesional skin of vitiligo patients before and after leflunomide treatment. Methods: Skin biopsies were taken from 16 active vitiligo patients before and after treatment with leflunomide for immunohistochemichal examinations of CD 20. Results: No CD20+ cells in skin biopsies either before or after treatment. Conclusions: Despite the known role of B lymphocyte in vitiligo, and the role of leflunomide in halting vitiligo activity, skin biopsies of active vitiligo lesions showed no B cells (CD 20+ cells) either before or after treatment with leflunomide. Keywords: Vitiligo; leflunomide; B-lymphocyte; skin biopsy; CD20. | ||
| Keywords | ||
| Vitiligo; leflunomide; B-lymphocyte; skin biopsy; CD20 | ||
|
Statistics Article View: 203 |
||
